NCT05426343View on ClinicalTrials.gov

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 9, 2022

Primary Completion Date

October 10, 2022

Study Completion Date

January 7, 2023

Conditions
COVID-19 Vaccine
Interventions
BIOLOGICAL

MVC-COV1901

Approximately 125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

BIOLOGICAL

AZD1222

Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Trial Locations (1)

Unknown

Hospital Fundación Tesai, Ciudad del Este

Sponsors
All Listed Sponsors
lead

Medigen Vaccine Biologics Corp.

INDUSTRY

NCT05426343 - A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222 | Biotech Hunter | Biotech Hunter